ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.
InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.